| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 503701 | 1 mg | $250 | ||
| 503702 | 5 mg | $750 | ||
| 503703 | 20 mg | $2000 |
| Clone | Minretumomab |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Minretumomab Biosimilar, TAG-72 Monoclonal Antibody |
| Isotype | Human IgG1 |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Immunogen | Human TAG-72 |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| See All Formats | Clone Minretumomab |
Minretumomab is a humanized monoclonal antibody belonging to the immunoglobulin G1 (IgG1) subclass, engineered to specifically recognize and bind to TAG-72 (tumor-associated glycoprotein 72). It consists of two identical heavy chains and two identical light chains joined by disulfide bonds, forming the typical Y-shaped antibody structure. Produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, it undergoes controlled post-translational modifications to ensure proper folding, stability, and glycosylation patterns essential for its biological function.
The variable regions of Minretumomab (the antigen-binding (Fab) fragments) contain complementarity-determining regions (CDRs) responsible for high-affinity recognition of TAG-72, a high-molecular-weight, mucin-like glycoprotein found on the surface of many cancer cells, particularly adenocarcinomas (breast, colon, pancreatic, ovarian, and lung).
The Fc–FcRn (neonatal Fc receptor) interaction provides extended serum half-life and molecular stability through recycling.
Anti-Human TAG-72 (Minretumomab Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
